{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269469","form_type":"8-K","ticker":"CARL","cik":"0001794546","company_name":"CARLSMED, INC.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.483691+00:00","generated_at":"2026-05-16T23:55:03.487018+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Carlsmed Q3 revenue $13.1M (up 98% YoY); raises FY2025 guidance to $49M-$50M","bullets":["Gross margin expanded to 75.9% from 72.8%; net loss of $8.5M vs $7.8M a year ago.","Cash $115.5M; amended debt facility to $50M with extended maturity and interest-only period.","CMS NTAP for cervical aprevo procedures effective Oct. 1, 2025; commercial launch expected early 2026.","Lead time for aprevo interbody implants reduced to 8 business days from 10 in Q2 2025.","Appointed Jennifer Kamocsay as Chief Legal Officer and Secretary."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269469","json":"https://secwatch.observer/filing/0001193125-25-269469.json","markdown":"https://secwatch.observer/filing/0001193125-25-269469.md","text":"https://secwatch.observer/filing/0001193125-25-269469.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1794546/000119312525269469/0001193125-25-269469-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1794546/000119312525269469/carl-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:55:03.487018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}